Article Text

Download PDFPDF
EP248 VALHUDES: a protocol for VALidation of HUman papillomavirus assays and collection DEvices for HPV testing on Self-samples and urine samples
  1. M Arbyn1,
  2. E Peeters1,
  3. G Donders2,
  4. P De Sutter3,
  5. W Tjalma4,
  6. S Weyers5,
  7. A Vorsters6,
  8. S Van Keer6,
  9. I Benoy7,
  10. D Vanden Broeck7,
  11. J-P Bogers7,
  12. C Cocuzza8,
  13. J Bonde9,
  14. M Poljak10,
  15. F Zhao11 and
  16. K Cuschieri12
  1. 1Sciensano, Brussels
  2. 2Hospital Tienen, Tienen
  3. 3University Hospital of Brussels, Brussels
  4. 4University Hospital of Antwerp, Antwerp
  5. 5University Hospital of Ghent, Ghent
  6. 6University of Antwerp
  7. 7Laboratory of Molecular Pathology, Antwerp, Belgium
  8. 8University of Milano-Bicocca, Monza, Italy
  9. 9Copenhagen University Hospital, Hvidovre, Denmark
  10. 10University of Ljubljana, Medical Faculty, Institute of Biochemistry, Ljubljana, Slovenia
  11. 11Beijing Tongeren Hospital, Beijing, China
  12. 12Royal Infirmary of Edinburgh, Edinburgh, UK


Introduction/Background Systematic reviews have concluded that hrHPV DNA testing using target-amplification tests is as accurate on vaginal self-samples as on clinician-taken specimens for the detection of cervical precancer. However, insufficient evidence is available for specific HPV assay/self-sample device combinations.

Methodology The VALHUDES protocol is designed as a diagnostic test accuracy study that aims to compare the clinical sensitivity and specificity of particular hrHPV assay(s) on vaginal self-samples and first-void-urine, collected in agreement with standardized protocols, with hrHPV testing on matched clinician-taken samples. Five hundred enrolled women referred to a colposcopy clinic are invited to collect a first-void urine sample and one or more vaginal self-samples with particular devices before collection of a cervical sample by a clinician. Sample sets are subsequently analysed in a laboratory accredited for HPV testing. Disease verification for all enrolled patients is provided by colposcopy combined with histological assessment of biopsies.

Results A first VALHUDES study has started in Belgium in December 2017 with enrolment from four colposcopy centres. The following assays are foreseen to be evaluated: RealTime High Risk HPV assay (Abbott), cobas-4800 and -6800 (Roche), Onclarity (BD), Xpert HPV (Cepheid) and Anyplex II HPV HR (Seegene).

Conclusion Given empirical evidence that the relative accuracy of HPV-testing on self- vs clinician-samples is robust across clinical settings, the VALHUDES protocol offers a framework for validation of HPV assay/self-sample device combinations that can be translated to a primary screening setting.

Disclosure A. Vorsters is co-founder and board member of Novosanis NV a spin-off of the University of Antwerp. M. Arbyn, E. Peeters, and M. Poljak are supported by the COHEAHR Network funded by the 7th Framework Programme of DG Research and Innovation, European Commission, Brussels, Belgium (grant No. 603019). M. Arbyn, E. Peeters, K. Cuschieri M. Poljak, and C. Cocuzza are supported by the SME Instrument Grant GA 80551, funded by the Horizon 2020 programme of DG Research and Innovation, European Commission, Brussels, Belgium. I. Benoy, D. Vanden Broeck and J. Bogers are employed by AML, a commercial lab performing cervical cytology and HPV testing.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.